One target limits complex tumor treatmentAntibody-drug conjugates have become an increasingly important part of cancer treatment. First, they administered either an EGFR-targeting antibody or a HER2 antibody that bound to one section of the receptor. About 24 hours later, the mice received another HER2 antibody that carried both a cancer-killing drug and the matching click component. The modified conjugates accumulated inside cancer cells at considerably higher levels than the original drugs. Further support came from the Alvin J. Siteman Cancer Center through The Foundation for Barnes-Jewish Hospital and the National Cancer Institute (P30 CA091842).